Evidence map›Paper›PMID 35773979›Full record

ArticleJournal of the International AIDS Society2022

PrEP user profiles, dynamics of PrEP use and follow-up: a cohort analysis at a Belgian HIV centre (2017-2020).

Anke Rotsaert, Thijs Reyniers, Bart K M Jacobs, Thibaut Vanbaelen, Christophe Burm, Chris Kenyon, Bea Vuylsteke, Eric Florence

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Relationship dynamics and behavioral adaptations in the control of the 2022 mpox epidemic.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Anke RotsaertDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-5895-9332
Thijs ReyniersDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Bart K M JacobsDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Thibaut VanbaelenDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Christophe BurmDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Chris KenyonDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Bea VuylstekeDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0003-0514-4372
Eric FlorenceDepartment of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Instituut voor Tropische Geneeskunde · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe number of individuals initiating antiretroviral pre-exposure prophylaxis (PrEP) is increasing, but we do not fully understand who is coming forward for PrEP, how they use it and how they are followed-up. The objective of this study was to examine PrEP user profiles, dynamics in PrEP use and follow-up over time.

methodsWe conducted a cohort analysis of longitudinally collected clinical record and questionnaire data among PrEP users at an HIV centre in Antwerp, Belgium, between June 2017 and March 2020. PrEP follow-up and user profiles were examined using descriptive analyses and bivariate logistic regression. We compared early adopting PrEP users (started before June 2018) with late users. We also calculated the probabilities of switching between daily and on-demand PrEP, and interruption, using a naïve estimator. RESULTS AND DISCUSSION: We included 1347 PrEP users in the analysis. After 12 months, retention in care was 72.3%. Median time between PrEP visits was 98 days (IQR 85-119 days). At screening visit, early adopting PrEP users (starting June 2017-May 2018) were significantly more likely to report one or more sexually transmitted infection in the prior 12 months, having used drugs during sex, a higher number of sexual partners and a history of paid sex and PrEP use prior to initiation, compared with PrEP users who initiated later (starting June 2018-February 2020). When taking PrEP daily, the probability of staying on daily PrEP at the next visit was 76%, while this was 73% when taking PrEP on-demand. Those using on-demand PrEP had a higher probability (13%) of interrupting PrEP care than daily PrEP users (7%), whereas those returning to PrEP care would mostly re-start with on-demand (35% vs. 13% for daily).

conclusionsThe majority of PrEP users in this sample remained in care after 12 months. The probability of remaining on the same PrEP regimen at the subsequent visit was high. Though, we observed a diversity of transitions between regimens and interruptions in between visits. Our findings reaffirm the need to provide tailored PrEP services, counselling PrEP users across their life course.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisSexual and Gender MinoritiesSexually Transmitted DiseasesBelgiumCohort StudiesHomosexuality, MaleHumansMaleAnti-HIV Agentscohort studiesEuropeHIV preventionmen who have sex with menPrEPretention

Identifiers

PMID35773979
PMCPMC9247302
OpenAlexW4283748906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.